Background/Aims: Among different molecular candidates, there is growing data to support that long noncoding RNAs (lncRNAs) play a significant role in acute myeloid leukemia (AML). HOXA-AS2 is significantly overexpressed in a variety of tumors and associated with anti-cancer drug resistance, however, little is known regarding the expression and function of HOXA-AS2 in the chemoresistance of AML. In this study, we aimed to determine the role and molecular mechanism of HOXA-AS2 in adriamycin-based chemotherapy resistance in AML cells. Methods: Quantitative real-time PCR was used to detect HOXA-AS2 expression in the BM samples and ADR cell lines, U/A and T/A cells. Furthermore, the effects of HOXA-AS2 silencing on cell proliferation and apoptosis were assessed in vitro by CCK8 and flow cytometry, and on tumor growth in vivo. Furthermore, bioinformatics online programs predicted and luciferase reporter assay were used to validate the association of HOXA-AS2 and miR-520c-3p in AML. Results: In this study, we showed that HOXA-AS2 is significantly upregulated in BM samples from AML patients after treatment with adriamycin-based chemotherapy and in U/A and T/A cells. Knockdown of HOXA-AS2 inhibited ADR cell proliferation in vitro and in vivo and promoted apoptosis. Bioinformatics online programs predicted that HOXA-AS2 sponge miR-520c-3p at 3’-UTR with complementary binding sites, which was validated using luciferase reporter assay and anti-Ago2 RIP assay. HOXA-AS2 could negatively regulate the expression of miR-520c-3p in ADR cells. S100A4 was predicted as a downstream target of miR-520c-3p, which was confirmed by luciferase reporter assay. Conclusion: Our results suggest that HOXA-AS2 plays an important role in the resistance of AML cells to adriamycin. Thus, HOXA-AS2 may represent a therapeutic target for overcoming resistance to adriamycin-based chemotherapy in AML.
A range of circular (Circ) RNAs have been demonstrated to be of therapeutic significance for the treatment of acute lymphoblastic leukemia (ALL). Here, we investigated the mechanisms underlying the action of Circ‐PRKDC and the microRNA‐653‐5p/Reelin (miR‐653‐5p/RELN) axis in T‐cell ALL (T‐ALL).Clinical specimens were obtained from patients with T‐ALL (n = 39) and healthy controls (n = 30). In each specimen, we determined the expression levels of Circ‐PRKDC, miR‐653‐5p, and RELN. Human T‐ALL cells (Jurkat) were transfected with Circ‐PRKDC‐ or miR‐653‐5p‐related sequences to investigate cell proliferation, apoptosis, and autophagy. We also determined the levels of Circ‐PRKDC, miR‐653‐5p, RELN, and signaling proteins related to phosphoinositide 3‐kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR). Finally, we decoded the interactions between Circ‐PRKDC, miR‐653‐5p, and RELN. The expression levels of Circ‐PRKDC and RELN were upregulated in T‐ALL tissues and cells while the levels of miR‐653‐5p were downregulated. Thereafter, then silencing of Circ‐PRKDC, or the enforced expression of miR‐653‐5p, repressed the expression of RELN and the activation of the PI3K/AKT/mTOR signaling pathway, thus enhancing cell autophagy and apoptosis, and disrupting cell proliferation. Circ‐PRKDC acted a sponge for miR‐653‐5p while miR‐653‐5p targeted RELN. The knockdown of miR‐653‐5p abrogated the silencing of Circ‐PRKDC‐induced effects in T‐ALL cells. The depletion of Circ‐PRKDC elevated miR‐653‐5p to silence RELN‐mediated PI3K/AKT/mTOR signaling activation, thereby enhancing autophagy and apoptosis in T‐ALL cells.
2 September 2021 in International Journal of Oncology
Acute myeloid leukemia (AML) is associated with a poor prognosis in elderly adults and currently lacks optimal treatment strategies. MicroRNAs (miRNAs or miRs) have increasingly been reported to be associated with AML progression; however, the mechanisms of action of miR‑93 in AML with the involvement of disabled 2 (DAB2) are currently unknown. In the present study, miR‑93 expression was assessed in patients with AML and in AML cell lines. The association between miR‑93 expression and the pathological characteristics of patients with AML was analyzed. AML cells were then transfected to knockdown or overexpress miR‑93 in order to elucidate its function in AML progression. The target gene of miR‑93 was assessed using a dual‑luciferase reporter gene assay. The expression levels of miR‑93, DAB2 and phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT) pathway‑related proteins were measured and in vivo experiments were conducted to confirm the results. It was observed that miR‑93 was highly expressed in patients with AML and in AML cells. The knockdown of miR‑93 in HL‑60 cells inhibited AML cell proliferation and resistance to apoptosis, while the overexpression of miR‑93 in THP‑1 cells led to contrasting results. Moreover, miR‑93 targeted DAB2 to inactivate the PI3K/AKT pathway, and the overexpression of DAB2 reversed the effects of miR‑93 on THP‑1 cell growth. Tumor volume, tumor weight, and the positive expression of Ki67, survivin and p53 were increased in THP‑1 cells overexpressing miR‑93. On the whole, the present study demonstrates that miR‑93 is highly expressed in AML cells, and that the suppression of miR‑93 inhibits AML cell growth by targeting DAB2 and inhibiting the PI3K/AKT pathway.
30 June 2021 in Bioscience, Biotechnology, and Biochemistry
Here, we aimed to investigate the biological roles and the regulatory mechanisms of miR-335-3p in acute myeloid leukemia (AML). We first found miR-335-3p was significantly downregulated in blood samples from leukemia patients and cell lines using reverse transcription quantitative polymerase chain reaction. Through CCK-8 assay and flow cytometry, we observed that miR-335-3p overexpression significantly inhibited cell proliferation and induced cell cycle G0/G1 arrest and apoptosis in AML cell lines (THP-1 and U937). Moreover, miR-335-3p directly targets EIF3E and negatively regulated its expression. More importantly, EIF3E overexpression reversed the effects of miR-335-3p on cell proliferation, G1/S transition, and apoptosis. Furthermore, miR-335-3p overexpression obviously downregulated the expression of CDK4, Cyclin D1, and Bcl-2, while upregulated the expression of p21 and Bad, which were significantly rescued by the cotransfection of pcDNA3.1-EIF3E. Collectively, our study proposes that miR-335-3p/EIF3E axis could be a promising therapeutic target to mitigate the progression of AML.